Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine-atropine-midazolam versus dexmedetomidine-atropine-midazolam for sedation during pediatric bone marrow biopsy
IRCT20250719066544N1Phase 3Completed
- Sponsor
- Qom University of Medical Sciences
- Start
- Jul 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ketamine, atropine, midazolam and dexmedetomidine (2 arms), sponsored by Qom University of Medical Sciences. Primary endpoints: Sedation level during sedation and procedure and Vital signs during sedation and procedure. Started Jul 2025; status: completed.
02
Drugs
ketamineatropinemidazolamdexmedetomidine
Beyond the preview
Go deeper on IRCT20250719066544N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250719066544N1.